NovaBay Pharmaceuticals (NBY)
(Delayed Data from AMEX)
$0.08 USD
0.00 (2.34%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.08 0.00 (1.52%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
NBY 0.08 0.00(2.34%)
Will NBY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NBY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for NBY
NovaBay Pharmaceuticals receives NYSE notice for compliance
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
NovaBay receives NYSE American notice of non-compliance
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses